SCHEMBL3499804

SCHEMBL3499804

CC(C)(C)OC(=O)c1oc2ccc(-c3ccc(Cl)cc3)cc2c1N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.60
ALDH1A1 P00352 8/20 0.60
HPGD P15428 7/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
HSD17B10 Q99714 6/20 0.51
HTT P42858 2/20 0.47
TP53 P04637 1/20 0.47
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
POLB P06746 1/20 0.42
MCL1 Q07820 1/20 0.42
MAPT P10636 5/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
USP2 O75604 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
AHR P35869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498056 0.80 KDM4E (0.60) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL20535014 0.80 KDM4E (0.78) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL3508906 0.80 KDM4E (0.57) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL3497298 0.79 KDM4E (0.49) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL2775680 0.76 KDM4E (0.70) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL4573629 0.75 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL3499961 0.74 KDM4E (0.61) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL3498599 0.73 KDM4E (0.61) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL3499014 0.72 MCL1 (0.78) KDM4EALDH1A1HPGDSMN1; SMN2TP53
SCHEMBL1854495 0.72 KDM4E (0.73) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 KDM4E 2059/4885ALDH1A1 3047/4885HPGD 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.